Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Immatics NV (IMTX)

Immatics NV (IMTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 12.19 (+0.16%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 12.19 (+0.16%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 12.19 (+0.16%)
Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

/PRNewswire / Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of...

IMTX : 12.19 (+0.16%)
PLX : 1.0900 (-0.91%)
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

Collaboration combines leading technologies to develop breakthrough, mRNA-enabled in vivo expressed TCER® molecules

MRNA : 69.86 (-2.96%)
IMTX : 12.19 (+0.16%)
Immatics: Q2 Earnings Snapshot

Immatics: Q2 Earnings Snapshot

IMTX : 12.19 (+0.16%)
Immatics: Q1 Earnings Snapshot

Immatics: Q1 Earnings Snapshot

IMTX : 12.19 (+0.16%)
Why Immatics Stock Is Soaring Today

Investors liked what they heard in Immatics' interim results for experimental immunotherapy IMA203.

IMTX : 12.19 (+0.16%)
Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases

Seamless Therapeutics today announced a $12.5 million (€11.8M) seed financing round which will accelerate further development of its designer recombinases, a novel gene editing platform to transform...

IMTX : 12.19 (+0.16%)
Immatics: Q3 Earnings Snapshot

Immatics: Q3 Earnings Snapshot

IMTX : 12.19 (+0.16%)

Barchart Exclusives

3 Top Dividend Stocks to Buy This September
After today's jumbo rate cut from the Fed, here are three dividend stocks to bolster your portfolio. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar